English 
Acute Kidney Injury (AKI) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00
Growth of the incidence AKI population will contribute to increasing sales in the AKI therapy market over our forecast period. An estimated annual growth rate of 2.68% in the diagnosed incident AKI population across the major pharmaceutical markets will contribute to increasing AKI therapy sales. In 2019, there were approximately 1.95 million diagnosed cases of AKI in the major markets; we expect the number of cases will exceed 2 million in 2032 owing to changes in population demographics and increasing cases of AKI associated conditions such as sepsis-AKI, Cardiac surgery-associated AKI and others.
The continuous involvement of supportive treatments including renal replacement therapies for the management of AKI patients will contribute to the the overall growth of the AKI therapy market. We forecast that total sales of the total care market will reach $XX billion by 2032.
Description
Acute kidney injury – AKI is common in hospitalized adults and children and associated with serious complications and high health care costs. Being hospitalized, especially for a serious condition that requires intensive care, advanced age, blockages in the blood vessels in arms or legs (peripheral artery disease), diabetes, high blood pressure, heart failure, kidney diseases, liver diseases, certain cancers and their treatments are the major causative factors that contributes to the incidence of AKI between different countries.
A better understanding of the molecular and cellular pathophysiological mechanisms underlying ischemic AKI is needed to provide a targeted approach to prevent and treat IR renal injury. Acute kidney injury (AKI) due to renal ischemia reperfusion (IR) is a serious clinical problem without effective therapy and is a significant and frequent cause of morbidity and mortality during the perioperative period. Renal ischemia and subsequent reperfusion injury initiates signaling cascades mediating renal cell necrosis, apoptosis, and inflammation, leading to AKI.
Acute Kidney Injury –AKI Epidemiology
Mellalta Meets has adopted the findings from a meta-analysis study conducted by International Society of Nephrology’s 0by25 initiative for acute kidney injury (Ravindra L Mehta, 2015). In the base year of our study period, we estimate an AKI prevalence of 275 per million people in Japan, 1811 per million in the five European markets covered in this report (France, Germany, Italy, Spain, and the United Kingdom), and 3000-5000 per million in the United States. In the United States, the estimated inpatient cost related to AKI is > $10 billion annually. The reported studies from high-income countries are focused on studies that defines AKI on the basis of the RIFLE, AKIN, and KDIGO diagnostic criteria, because they allow a more accurate ascertainment of the incidence and outcomes of AKI in high-income countries, therefore, we expect 100% diagnosis rate. Therefore, we hold our diagnosed and treatment cases estimates constant over the forecast period, and changes in the number of AKI cases are due to demographic shifts.
Acute Kidney Injury–AKI Market Forecast
The Acute Kidney Injury (AKI) therapy market is expected to experience high growth throughout our study period, increasing from $XX billion in 2019 to $XX billion in 2030, representing 2.6% annual growth. Primary drivers of this growth will be uptake of the novel 6 months treatment i.e. Refanalin (Angion), teprasiran (Quark/Novartis), bRESCAP (Alloksys), recAP (AM Pharma), Conestat alfa (Pharming) and ASP-1128 (Astellas), along with an expanding number of AKI cases associated with sepsis, Cardiac surgery and contrast induced angiography (CIN), CIVID-19 associated AKI and delayed graft function (DGF), predominantly in the United States.
Most interviewed experts believe, that patients will benefit from the upcoming therapies launching in the Sepsis-associated AKI (SA-AKI), Cardiac Surgery associated AKI (CSA-AKI) and others including, delayed graft function and for the prevention of the contrast induced AKI (CA-AKI) in coronary angiography. Refanalin(Angion) will be the first therapy which will be launched in the market for CSA-AKI and will have first mover advantage over other therapies which are launching in same space such as teprasiran (Quark/Novartis), ASP-1128 (Astellas) and bRESCAP (Alloksys). We also believe that the drug will begin facing competition with its peer therapies as physicians’ preference for these agents in terms of knowledge of efficacy and safety grows.
Report Highlights
- Acute Kidney Injury–AKI Current Market Trends
- Acute Kidney Injury–AKI Current & Forecasted Cases across the G7 Countries
- Acute Kidney Injury–AKI Market Opportunities And Sales Potential for Agents
- Acute Kidney Injury–AKI Patient-based Market Forecast to 2032
- Acute Kidney Injury–AKI Untapped Business Opportunities
- Acute Kidney Injury–AKI Product Positioning Vis-a-vis Competitors’ Products
- Acute Kidney Injury–AKI KOLs Insight
Additional information
| Price | Single User License, 2-3 User License, Site License, Enterprise License |
|---|
Table of Contents
- Acute Kidney Injury Disease Background
- Acute Kidney Injury Definition
- Symptoms
- Risk Factor
- Diagnosis
- Epidemiology Estimated and Forecast to 2030
- Epidemiology Research Method & Data Sources Used
- Incident Cases of Acute Kidney Injury in the United States 2022-2032
- Cases of Acute Kidney Injury by AKI-Associated Conditions in the United States 2022-2032
- Incident Cases of Acute Kidney Injury in Germany 2022-2032
- Cases of Acute Kidney Injury by AKI-Associated Conditions in Germany 2022-2032
- Incident Cases of Acute Kidney Injury in France 2022-2032
- Cases of Acute Kidney Injury by AKI-Associated Conditions in France 2022-2032
- Incident Cases of Acute Kidney Injury in Italy 2022-2032
- Cases of Acute Kidney Injury by AKI-Associated Conditions in Italy 2022-2032
- Incident Cases of Acute Kidney Injury in Spain 2022-2032
- Cases of Acute Kidney Injury by AKI-Associated Conditions in Spain 2022-2032
- Incident of Acute Kidney Injury in the United Kingdom 2022-2032
- Cases of Acute Kidney Injury by AKI-Associated Conditions in the United Kingdom 2022-2032
- Incident Cases of Acute Kidney Injury in Japan 2022-2032
- Cases of Acute Kidney Injury by AKI-Associated Conditions in Japan 2022-2032
- Epidemiology Research Method & Data Sources Used
- Current Unmet Needs in Acute Kidney Injury
- Current Treatment Paradigm
- Treatment guidelines for Acute Kidney Injury
- Management of RRT in Acute Kidney Injury
- Emerging Therapies Chapters
- alkaline phosphatase, AM-Pharma
- ASP 1128, Astellas
- refanalin, Angion
- teprasiran, Quark Therapeutics
- Bovine intestinal alkaline phosphatase, Alloksys
- reltecimod, AtoxBio
- EA-230, Exponential Biotherapies
- conestat alfa, Pharming
- DUR-928, Durect
- SBI-10, Sentien Biotechnologies
- AKI Product Positioning
- Key Competitors
- Matrix Modeling
- Total Market Forecast
- Key Summary Findings
- G7 total Market for Acute Kidney Injury 2022-2032 (USD Million)
- G7 total Market for Acute Kidney Injury by Therapies 2022-2032 (USD Million)
- Key Summary Findings
- Market Forecast by Country
- United States
- United States Market for Acute Kidney Injury 2022-2032 (USD Million)
- United States Market for Acute Kidney Injury by Therapies 2022-2032 (USD Million)
- Germany
- Germany Market for Acute Kidney Injury 2022-2032 (USD Million)
- Germany Market for Acute Kidney Injury by Therapies 2022-2032 (USD Million)
- France
- France Market for Acute Kidney Injury 2022-2032 (USD Million)
- France Market for Acute Kidney Injury by Therapies 2022-2032 (USD Million)
- Italy
- Italy Market for Acute Kidney Injury 2022-2032 (USD Million)
- Italy Market for Acute Kidney Injury by Therapies 2022-2032 (USD Million)
- Spain
- Spain Market for Acute Kidney Injury 2022-2032 (USD Million)
- Spain Market for Acute Kidney Injury by Therapies 2022-2032 (USD Million)
- United Kingdom
- United Kingdom Market for Acute Kidney Injury 2022-2032 (USD Million)
- United Kingdom Market for Acute Kidney Injury by Therapies 2022-2032 (USD Million)
- Japan
- Japan Market for Acute Kidney Injury 2022-2032 (USD Million)
- Japan Market for Acute Kidney Injury by Therapies 2022-2032 (USD Million)
- United States
- Market Drivers & Barriers
- Appendix
Sample Enquiry
Related products
-
Corticobasal Syndrome (CBS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsCorticobasal syndrome (CBS) is characterized by lowest clinical diagnostic accuracy, with the highest clinical presentation found in corticobasal degeneration (CBD). Current Corticobasal syndrome (CBS) treatment is limited to levodopa, commonly prescribed medication for the treatment of Parkinson’s disease. Thus, there is a huge unmet need for a medical treatment to improve the quality of life. Emerging therapies like Rho-kinase inhibitor- Fasudil (Woolsey Pharmaceuticals) have the potential to overcome the treatment barrier. Corticobasal syndrome market size will reflect high growth from 2025-2030 due to launch of Fausdil (Woolsey) in the market from 2025 year.
-
Head and neck squamous cell carcinoma (HNSCC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2033
$7,500.00 – $22,500.00Select optionsAccording to Mellalta Meets Analyst’s most recent estimate, the Head and neck squamous cell carcinoma (HNSCC) therapeutics market for HNSCC s was worth US$ Billion in 2023 and is predicted to grow at a 13.9% CAGR to reach US$ 7.5 Billion by 2033.
-
Mitochondrial Epilepsy (MIT-E) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Mitochondrial epilepsy (MIT-E) therapeutic market is expected to increase at a significant rate during the figure time frame, 2022 to 2032. In 2022, the market is developing at a consistent rate and the market is relied upon to ascend over the projected horizon with the rise in adoption strategies by key market players. The therapy market is expected to experience high growth throughout our study period, increasing from 2018 to 2032. -
Peripheral T-cell lymphoma (PTCL)| Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsMellalta’s analysts estimate that the United States market is expected to show rapid growth, mainly attributed to, the launch of Adcetris in the front-line setting and expected approval of the potential therapies in the pipeline during the forecast period (2021-2030). Through this, the market size is set to show an extensive jump and grow at a CAGR of 15.3%